Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial.

ABSTRACT: Osteosarcoma is a highly heterogeneous cancer, and molecular subtyping has the potential to increase diagnostic precision and facilitate targeted therapies. In our previous study, we classified osteosarcoma into four distinct subtypes. Here, we conducted a genomic subtype-guided pilot umbrella trial (ChiCTR2000036618, 2020/08/24) to evaluate the efficacy and safety of multiple precision therapies. Nineteen patients with refractory metastatic osteosarcoma were enrolled and stratified using whole-exome sequencing (WES) and immunohistochemistry (IHC). Patients were assigned to three arms: (A) PD-1 antibody plus gemcitabine and docetaxel; (B) PARP inhibitor combined with temozolomide; or (C) tinengotinib (TT-00420), a small-molecule aurora kinase inhibitor currently in clinical trials. The med

SUBMITTER: Tian K 

PROVIDER: S-EPMC12804796 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature